Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 2

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 2
---
 now working to maximize value of the asset Talent and Culture: Optimizing Our Leadership Team Appointed Neil McFarlane as Chief Executive Officer following a thorough process to find the right leader to accelerate Zevra’s progress and harness our pipeline Appointed Rahsaan Thompson as Chief Legal Officer and Alison Peters as Chief People Officer Consolidated development and scientific functions under new Chief Medical Officer Adrian Quartel Commercial Excellence: Delivering Excellence With the Launch of Our First Two Commercial Products Obtained approval in September 2024 from the U.S. Food and Drug Administration for MIPLYFFA This follows our successful introduction of OLPRUVA, Zevra’s first-ever commercial launch, following approval in December 2022 Your Board and Management Team’s Strategic Plan to Transform Zevra into a Leading Rare Disease Company

Stockholders Have Two Options: Risk Disruption by a Single Stockholder with No Stated Strategy or A Proven Team With a Clear Strategy and Strong Momentum If Mangless’ two nominees are elected this year, his nominees would have five of eight Board seats in total, raising questions over control and the amount of undue influence one stockholder should have on the Board Lacks strategies, plans, or new ideas to improve Zevra’s business Mangless’ nominees massively destroyed stockholder value in previous roles Mangless’ nominees either lack independence, business experience, and/or necessary expertise to oversee a highly specialized rare disease company like Zevra Achieved key milestones in the last two years Delivered superior returns for stockholders Continued execution of strategy, focused on creating long-term value Highly engaged and refreshed Board Directors are exceptionally qualified, independent, and have track records of value creation

Delivering Value to Stockholders and Patients Advancing our Mission of Becoming a Leading Rare Disease Company 1 2 Our Refreshed Board Oversees a Purpose-Built Management Team 3 Mangless’ Nominees are Not Qualified for Zevra’s Board 4 Table of Contents

Delivering Value to Stockholders and Patients 1

PHASE 1 PHASE 2 PHASE 3 NDA/MAAiv FDA Approved Status and IP KP1077 Idiopathic Hypersomnia (IH) KP1077 Narcolepsy AZSTARYS® serdexmethylphenidate and dexmethylphenidate Attention Deficit Hyperactivity Disorder (ADHD) Celiprolol Vascular Ehlers-Danlos Syndrome (VEDS) Certain products may be subject to royalty obligations, details and required disclosures are available in our SEC filings or